Calcium Channel Blocker Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Calcium Channel Blocker Market Analysis
The Calcium Channel Blocker Market is expected to register a CAGR of 5.1% during the forecast period.
The pandemic had a significant effect on market growth. For instance, the research study from Nature Journal published in January 2022 reported that anxiety related to the COVID-19 pandemic was linked to a temporary rise in the morning sleep blood pressure (SBP) among older patients and increased risk of cardiovascular events throughout the 1-year follow-up. As a result, continuous blood pressure monitoring became necessary both during and after the pandemic, which increased the demand for calcium channel blockers. Additionally, several projects involving blood pressure were initiated in 2020-21 to improve and support blood pressure. For example, the American Heart Association received USD 32 million in December 2020 through a series of cooperative agreements with the United States Department of Health and Human Services for a national initiative to improve COVID-19-related health outcomes by reducing high blood pressure among racial and ethnic populations, who have higher rates of high blood pressure and are at increased risk for COVID-19 and severe chronic conditions such as heart disease. Thus, the market had a significant impact on the market studied. However, currently, the market studied has reached its pre-pandemic stage in terms of demand for the products and is believed to witness strong growth in coming years.
The increasing prevalence rate of cardiovascular diseases and changing lifestyles of people are expected to boost the calcium channel blocker market growth.
Various research studies have been published to provide insight into calcium channel blockers. For instance, according to a research study by PubMed published in May 2022, calcium channel blockers (CCBs) like amlodipine significantly increase the therapeutic responses to gemcitabine in orthotopic xenografts and transgenic models of pancreatic ductal adenocarcinoma by inhibiting prosurvival Epidermal Growth Factor Receptor (EGFR). Therefore, the use of calcium channel blockers is increasing in orthopedic xenografts.
Hypertension, often referred to as elevated blood pressure, is one of the major causes associated with heart disease. Increasing heart disease is another factor in market growth. For instance, according to a news release issued by Boehringer Ingelheim GmbH in August 2021, heart failure is a chronic, incapacitating cardio-renal-metabolic disease that affects about 60 million individuals or more worldwide. As the prevalence of heart failure continues to rise, new therapeutic options are desperately needed. As a result, there was a global demand for the pharmaceuticals available to treat hypertension, which fueled the rise of the market under investigation. Thus, the abovementioned factors are expected to increase the market growth.
However, product recalls in recent years may hinder the market growth.
Calcium Channel Blocker Market Trends
This section covers the major market trends shaping the Calcium Channel Blocker Market according to our research experts:
Hospitals Segment Expected to Hold a Major Share in the Calcium Channel Blocker Market
A hospital also referred to as a medical centre, is a healthcare institution providing treatment with specialized medical and nursing staff and medical equipment. Factors such as increasing cases of hypertension, along with an increasing number of hospitals and initiatives by the public organization, are expected to increase the market growth. For instance, according to the American Hospital Association, 2021, the total number of all United States Hospitals was 6,090. More than 700 million individuals around the world have untreated hypertension, according to data updated by the World Health Organization (WHO) in August 2021, and 1.28 billion people worldwide had hypertension, a sharp increase over the previous few decades.
Additionally, hypertension considerably raises the risk of renal, heart, and brain problems, according to the WHO publication. As a result, there is an increase in demand for medications used to manage hypertension, which is anticipated to propel the segment's expansion. In August 2022, Prime Minister Narendra Modi inaugurated Amrita Hospital in Haryana, which is claimed to be India's largest private hospital with 2,600 beds. The super-speciality hospital is equipped with the latest healthcare facilities. With an increasing number of large hospitals, it is believed that the care provided to patients will also improve, which will boost the segment growth in the coming years.
Thus, the abovementioned factors are likely to increase the market growth.
North America Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global calcium Channel blocker market due to changing lifestyles among people and the increasing prevalence rate of cardiovascular diseases.
The adoption of a sedentary lifestyle has serious implications for the health of people and is known to cause diseases related to cardiovascular diseases, obesity, high blood pressure, etc. For instance, according to the Pan American Health Organization (PAHO) for 2021, ischemic heart disease and stroke were the leading causes of mortality and a significant factor in disability in the Americas. Cardiovascular diseases (CVD) are also one of the main causes of death and disability worldwide. According to the same source as above, ischemic heart disease is a significant cause of 73.6 fatalities per 100,000 people. In the Americas, 40.8 million disability-adjusted life years (DALYs) are caused each year by cardiovascular illnesses. Thus, to prevent such high mortality, the adoption of hypertension-prevention drugs is expected to increase. This is expected to increase market growth in the upcoming future.
The increasing burden of hypertension is augmenting the emergence of new initiatives by the government to cope with the condition. For instance, Mexico formally endorsed the HEARTS project in February 2020. The Pan American Health Organization/World Health Organization (PAHO/WHO) is supporting the effort, which aims to improve primary care-level hypertension prevention and management. The goal is to reduce the burden of chronic diseases and get closer to achieving the Sustainable Development Goals by 2030. Such a program is expected to increase the need for blood pressure medications in the nation, which will help to fuel the rising need for calcium channel blockers. Thus, the abovementioned factors are expected to increase the market growth.
Calcium Channel Blocker Industry Overview
The calcium channel blocker market is fragmented and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies currently dominating the market include Pfizer Inc., Alvogen, Abbvie Inc., Exela, Pharma Sciences LLC, Bausch Health Company Inc., GlaxoSmithKline LLC, Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, and Arbor Pharmaceuticals LLC.
Calcium Channel Blocker Market Leaders
-
Pfizer Inc.
-
Abbvie Inc.
-
Silvergate Pharmaceuticals Inc.
-
Novartis AG
-
GlaxoSmithKline
*Disclaimer: Major Players sorted in no particular order
Calcium Channel Blocker Market News
- Jun 2022: CMP Pharma announced that Norliqva (Amlodipine) Oral Solution, 1 mg/mL, the first and only FDA-approved oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker, is available. Norliqva was approved by the FDA on February 24, 2022, and is now available through normal retail distribution.
- May 2022: The United States Food and Drug Administration (US FDA) gave Zydus Worldwide DMCC's subsidiary preliminary approval to market Selexipag tablets for the treatment of pulmonary arterial hypertension (PAH) in adults.
Calcium Channel Blocker Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Burden of Cardiovascular Diseases
- 4.2.2 Changing Lifestyles of People
-
4.3 Market Restraints
- 4.3.1 Product Recalls
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Drug Class
- 5.1.1 Dihydropyridine
- 5.1.2 Benzothizepine
- 5.1.3 Phenylalkylamine
-
5.2 By Distribution Channel
- 5.2.1 Hospitals
- 5.2.2 Retail Pharmacies
- 5.2.3 Other Distribution Channels
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbvie Inc.
- 6.1.2 Alvogen
- 6.1.3 Arbor Pharmaceuticals LLC
- 6.1.4 Bausch Health Company Inc.
- 6.1.5 Covis Pharma BV
- 6.1.6 Exela Pharma Sciences LLC
- 6.1.7 GlaxoSmithKline LLC
- 6.1.8 Lupin Pharmaceuticals Inc.
- 6.1.9 Novartis AG
- 6.1.10 Pfizer Inc.
- 6.1.11 Sanofi
- 6.1.12 Silvergate Pharmaceuticals Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCalcium Channel Blocker Industry Segmentation
As per the scope, calcium channel blockers/ calcium antagonists are drugs that are used against indications such as hypertension and chest pain. It slows the calcium movement that helps to widen the blood vessels and makes it easier for the heart to pump blood. The Calcium Channel Blocker Market is Segmented By Drug Class (Dihydropyridine, Benzothizepine, Phenylalkylamine), Distribution Channel (Hospitals, Retail Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Drug Class | Dihydropyridine | |
| Benzothizepine | ||
| Phenylalkylamine | ||
| By Distribution Channel | Hospitals | |
| Retail Pharmacies | ||
| Other Distribution Channels | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Calcium Channel Blocker Market Research FAQs
What is the current Calcium Channel Blocker Market size?
The Calcium Channel Blocker Market is projected to register a CAGR of 5.10% during the forecast period (2024-2029)
Who are the key players in Calcium Channel Blocker Market?
Pfizer Inc., Abbvie Inc., Silvergate Pharmaceuticals Inc., Novartis AG and GlaxoSmithKline are the major companies operating in the Calcium Channel Blocker Market.
Which is the fastest growing region in Calcium Channel Blocker Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Calcium Channel Blocker Market?
In 2024, the North America accounts for the largest market share in Calcium Channel Blocker Market.
What years does this Calcium Channel Blocker Market cover?
The report covers the Calcium Channel Blocker Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Calcium Channel Blocker Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Calcium Channel Blocker Industry Report
Statistics for the 2024 Calcium Channel Blocker market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Calcium Channel Blocker analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
